Elotuzumab
- Generic Name
- Elotuzumab
- Brand Names
- Empliciti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 915296-00-3
- Unique Ingredient Identifier
- 1351PE5UGS
- Background
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. ...
- Indication
Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
- Associated Conditions
- Refractory Multiple Myeloma
- Associated Therapies
- -
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Omar Nadeem, MD
- Target Recruit Count
- 49
- Registration Number
- NCT06518551
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Celgene
- Registration Number
- NCT06232707
- Locations
- 🇺🇸
Local Institution - 0088, Los Angeles, California, United States
🇺🇸Local Institution - 0324, Baltimore, Maryland, United States
🇦🇺Local Institution - 0022, Waratah, New South Wales, Australia
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 795
- Registration Number
- NCT06208150
- Locations
- 🇨🇳
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
🇨🇳Tongji Hospital, Tongji Medical College of HUST, Wuhan, China
🇮🇱Carmel Medical Center, Haifa, Israel
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 380
- Registration Number
- NCT06158841
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 260883, Hangzhou, Zhejiang, China
🇺🇸Alta Bates Summit Medical Center for Research /ID# 261438, Berkeley, California, United States
🇺🇸Providence - St. Jude Medical Center /ID# 262031, Fullerton, California, United States
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Conditions
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 492
- Registration Number
- NCT06152575
- Locations
- 🇺🇸
Community Health Network, Inc., Indianapolis, Indiana, United States
🇺🇸Cayuga Cancer Center at Cayuga Park, Ithaca, New York, United States
🇺🇸Cayuga Medical Center, Ithaca, New York, United States
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 380
- Registration Number
- NCT05730036
- Locations
- 🇧🇪
Ziekenhuis Netwerk Antwerpen Campus Stuivenberg, Antwerp, Belgium
🇵🇱Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Lubelskie, Poland
🇺🇸UCLA, Los Angeles, California, United States
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 7
- Registration Number
- NCT05560399
- Locations
- 🇺🇸
Icahn School of Medicine, New York, New York, United States
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 222
- Registration Number
- NCT05028348
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸California Cancer Associates for Research and Excellence, Encinitas, California, United States
🇺🇸University of California, San Francisco, Fresno, California, United States
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Yale University
- Target Recruit Count
- 24
- Registration Number
- NCT05002816
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2024-01-11
- Target Recruit Count
- 8
- Registration Number
- NCT04918147
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Mayo Clinic: Pulmonary and Critical Care Medicine, Rochester, Minnesota, United States
🇺🇸Emory Healthcare, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.